NSCLC
542
135
184
127
Key Insights
Highlights
Success Rate
70% trial completion
Published Results
42 trials with published results (8%)
Research Maturity
127 completed trials (23% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.0%
54 terminated out of 542 trials
70.2%
-16.4% vs benchmark
9%
49 trials in Phase 3/4
33%
42 of 127 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 127 completed trials
Clinical Trials (542)
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients
A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib
Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC
JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC
A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers